FDA authorizes expanded access for NRX‑101, a fixed‑dose D‑cycloserine/lurasidone combination, enabling treatment‑resistant depression patients to receive therapy with accelerated TMS outside clinical trials.
Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
NRx Pharmaceuticals has secured U.S. Food and Drug Administration (FDA) authorization for an Intermediate Population Expanded Access Protocol for NRX-101, its investigational fixed-dose combination of D-cycloserine (DCS) and lurasidone. The protocol enables eligible patients with treatment-resistant depression (TRD) to receive NRX-101 in combination with accelerated transcranial magnetic stimulation (TMS) outside of a clinical trial setting.
The authorization comes as the company advances its pivotal Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) study, which will evaluate whether NRX-101 can improve remission rates for depression and suicidality when added to neuronavigated robotic TMS in both civilian and military treatment centers.
Clinical Rationale: DCS as Neuroplasticity Adjunct
Treatment-resistant depression remains a major unmet medical need, particularly among patients who continue to experience severe depressive symptoms and suicidal thoughts despite standard therapies. Although TMS has emerged as an important noninvasive treatment option, many patients fail to achieve sustained remission.
Growing clinical evidence suggests that D-cycloserine may enhance the therapeutic effects of TMS. Several published studies have reported improved remission outcomes when DCS is used alongside TMS in patients with depression and suicidality.
DCS is known to influence glutamatergic signaling and promote neuroplasticity, the brain’s ability to form and strengthen neural connections. Neuroplastic changes are believed to play a central role in reversing depressive symptoms and reducing suicidal ideation. NRX-101 combines DCS with lurasidone, an atypical antipsychotic, in a proprietary formulation intended to support these neuroplastic mechanisms.
Expanded Access Pathway and SPARC‑TMS Trial
The newly authorized Expanded Access Program provides a regulated pathway for patients who cannot enroll in the ongoing SPARC-TMS trial. Under the program, participating physicians may offer GMP-manufactured NRX-101 alongside accelerated TMS treatment.
The company noted that the low DCS doses used for neuropsychiatric applications are not commercially available through approved products. This has contributed to increased use of compounded DCS formulations. However, compounded medicines are not reviewed by the FDA for quality, stability, or impurity control.
According to NRx, development of NRX-101 required extensive formulation work to prevent degradation of DCS and ensure long-term product stability. The expanded access program will initially provide the investigational therapy at no drug cost, with participating sites responsible only for shipping and FDA-mandated data collection expenses.
Expert Perspective on Access and Evidence
Joshua Brown, MD, PhD, Chief Medical Innovation Officer at NRx Pharmaceuticals, highlighted the FDA’s support for broader access to regulated, GMP-manufactured DCS during clinical development. He emphasized the importance of generating robust evidence through the SPARC-TMS trial while making the investigational therapy available to patients with limited treatment options.
Brown also noted the growing clinical interest in DCS as a neuroplasticity-enhancing adjunct to TMS and its potential role in improving outcomes for patients with severe depression and suicidality.
Toward Regulatory Submission
Enrollment and execution of the SPARC-TMS pivotal study now represent the key next milestones for NRX Pharmaceuticals. Positive results could support a future regulatory submission for NRX-101 as an adjunctive therapy to TMS in treatment-resistant depression. In parallel, the expanded access program offers an opportunity to provide investigational treatment to eligible patients while additional efficacy and safety data continue to accumulate.
What This Means for Patients
For individuals living with treatment‑resistant depression particularly those who continue to struggle with severe symptoms or suicidal thoughts despite standard therapies—the FDA’s Expanded Access Program offers a potential new avenue of care before NRX‑101 completes full clinical development.
Patients unable to enroll in the pivotal SPARC‑TMS trial may now gain access to investigational NRX‑101 in combination with accelerated TMS through participating physicians. This pathway provides a regulated, GMP‑manufactured formulation of D‑cycloserine, addressing concerns over compounded alternatives that lack FDA oversight for quality and stability.
While NRX‑101 remains investigational and its benefits and risks are still under evaluation, the program represents a meaningful opportunity for eligible patients with limited options. Under physician supervision, they may receive therapy designed to enhance neuroplasticity and potentially improve remission outcomes, even as larger trials continue to generate the evidence needed for future regulatory review.
Reference
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.